Portal de Periódicos da CAPES

Liver metastases and immunotherapy: A barrier to response for metastatic melanoma

2022; Wiley; Volume: 37; Issue: 2 Linguagem: Inglês

10.1111/jdv.18590

1468-3083

Marco Rubatto, Nicole Macagno, Ginevra Pastorin, Paolo Fava, Luca Ceroni, Simone Ribero, Pietro Quaglino,

Cutaneous Melanoma Detection and Management

Journal of the European Academy of Dermatology and VenereologyVolume 37, Issue 2 p. e186-e188 LETTER TO THE EDITOR Liver metastases and immunotherapy: A barrier to response for metastatic melanoma Marco Rubatto, Corresponding Author Marco Rubatto [email protected] orcid.org/0000-0003-1706-656X Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, Italy Correspondence Marco Rubatto, Department of Medical Sciences, Dermatologic Clinic, University of Turin, Via Cherasco 23, 10126 Turin, Italy. Email: [email protected]Search for more papers by this authorNicole Macagno, Nicole Macagno orcid.org/0000-0002-0097-2139 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this authorGinevra Pastorin, Ginevra Pastorin Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this authorPaolo Fava, Paolo Fava orcid.org/0000-0002-8443-7458 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this authorLuca Ceroni, Luca Ceroni University of Turin, Torino, ItalySearch for more papers by this authorSimone Ribero, Simone Ribero orcid.org/0000-0002-0098-1406 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this authorPietro Quaglino, Pietro Quaglino orcid.org/0000-0003-4185-9586 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this author Marco Rubatto, Corresponding Author Marco Rubatto [email protected] orcid.org/0000-0003-1706-656X Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, Italy Correspondence Marco Rubatto, Department of Medical Sciences, Dermatologic Clinic, University of Turin, Via Cherasco 23, 10126 Turin, Italy. Email: [email protected]Search for more papers by this authorNicole Macagno, Nicole Macagno orcid.org/0000-0002-0097-2139 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this authorGinevra Pastorin, Ginevra Pastorin Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this authorPaolo Fava, Paolo Fava orcid.org/0000-0002-8443-7458 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this authorLuca Ceroni, Luca Ceroni University of Turin, Torino, ItalySearch for more papers by this authorSimone Ribero, Simone Ribero orcid.org/0000-0002-0098-1406 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this authorPietro Quaglino, Pietro Quaglino orcid.org/0000-0003-4185-9586 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Torino, ItalySearch for more papers by this author First published: 25 September 2022 https://doi.org/10.1111/jdv.18590 Marco Rubatto and Nicole Macagno shared first authorship. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Wang C, Sandhu J, Ouyang C, Ye J, Lee PP, Fakih M. Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases. JAMA Netw Open. 2021; 4(8):e2118416. 10.1001/jamanetworkopen.2021.18416 PubMedWeb of Science®Google Scholar 2Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016; 62: 132–7. https://doi.org/10.1016/j.ejca.2016.03.081 10.1016/j.ejca.2016.03.081 PubMedWeb of Science®Google Scholar 3Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021; 27(1): 152–64. https://doi.org/10.1038/s4159-020-1131-x 10.1038/s4159?020?1131?x CASPubMedWeb of Science®Google Scholar 4Lindblad KE, Lujambio A. Liver metastases inhibit immunotherapy efficacy. Nat Med. 2021; 27(1): 25–7. https://doi.org/10.1038/s41591-020-01190-9 10.1038/s41591?020?01190?9 CASPubMedWeb of Science®Google Scholar 5Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019; 452: 66–70. https://doi.org/10.1016/j.canlet.2019.02.048 10.1016/j.canlet.2019.02.048 CASPubMedWeb of Science®Google Scholar Volume37, Issue2February 2023Pages e186-e188 ReferencesRelatedInformation